|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.
|
29246445 |
2018 |
|
Liver Failure, Acute
|
0.300 |
Biomarker
|
disease |
CTD_human |
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.
|
29246445 |
2018 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.
|
29246445 |
2018 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.
|
29246445 |
2018 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.
|
29246445 |
2018 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.
|
29246445 |
2018 |
|
Autosomal Recessive Polycystic Kidney Disease
|
0.200 |
Biomarker
|
disease |
RGD |
Knockout of
|
31630543 |
2019 |
|
Hypothyroidism
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Colitis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
All the C57BL/6 mice were allocated into groups as follows: control group, colitis model group, colitis treated with salazosulfapyridine (SASP) group, and colitis treated with MRS (1 or 10 ml/kg) groups.
|
31182999 |
2019 |
|
Colitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis.
|
22426419 |
2012 |
|
Colitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Materials and Methods:</b> Healthy human colonic mucosal strips (4 × 10 mm) were incubated in carbogenated culture medium at 37°C for 16 h. Proinflammatory cytokines TNFα and IL-1β (each 10 ng/mL) were used to induce colitis in mucosal strips, and the effects of Panx1 and P2X7R on cytokines-induced tissue damage were determined in the presence of the Panx1 channel blocker <sup>10</sup>Panx1 (100 μM) and P2X7R antagonist A438079 (100 μM).
|
30127744 |
2018 |
|
Epilepsy
|
0.030 |
Biomarker
|
disease |
BEFREE |
This review examines the critical and complex roles of Panx1 channels in epilepsy, which could provide a basis for future therapeutics.
|
28886985 |
2019 |
|
Epilepsy
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We studied the impact of pannexin-1 channel activation in postoperative human tissue samples from patients with epilepsy displaying epileptic activity ex vivo.
|
29848662 |
2018 |
|
Epilepsy
|
0.030 |
Biomarker
|
disease |
BEFREE |
Increasing evidence suggests that the large-pore ion channels, pannexin 1 (Panx1) and 2 (Panx2), are involved in epilepsy and brain development.
|
28036289 |
2017 |
|
Septicemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
An overexpression of Panx-1 channel might be responsible for the strong inflammatory response, high serum ATP level, and skeletal muscle cellular energy crisis and histopathological damages in sepsis.
|
30014232 |
2018 |
|
Septicemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these findings suggested that elevated macrophage Panx1 expression and hemichannel activation contribute to the pathogenesis of lethal sepsis.
|
30655582 |
2019 |
|
Septicemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sepsis was induced in wild-type C57BL/6 mice by cecal ligation and puncture (CLP), and the mice were divided into three groups: a sham control group (sham), a surgery group with saline intraperitoneal injection (i.p.) treatment (CLP + NS), and a surgery group with MRS i.p. treatment (CLP + MRS).
|
30581532 |
2018 |
|
Sepsis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these findings suggested that elevated macrophage Panx1 expression and hemichannel activation contribute to the pathogenesis of lethal sepsis.
|
30655582 |
2019 |
|
Sepsis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sepsis was induced in wild-type C57BL/6 mice by cecal ligation and puncture (CLP), and the mice were divided into three groups: a sham control group (sham), a surgery group with saline intraperitoneal injection (i.p.) treatment (CLP + NS), and a surgery group with MRS i.p. treatment (CLP + MRS).
|
30581532 |
2018 |
|
Sepsis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
An overexpression of Panx-1 channel might be responsible for the strong inflammatory response, high serum ATP level, and skeletal muscle cellular energy crisis and histopathological damages in sepsis.
|
30014232 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest PANX1 overexpression in breast cancer is associated with a shift towards an EMT phenotype, in silico and in vitro, attributing to it a tumor-promoting effect, with poorer clinical outcomes in breast cancer patients.
|
31817827 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, small-molecule therapeutic inhibition of PANX1 channels is found to reduce the efficiency of breast cancer metastasis.
|
26098574 |
2015 |
|
Ulcerative Colitis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the colonic muscularis of ulcerative colitis (UC), Panx1 mRNA expression showed a 3.5-fold reduction compared with control (P = 0.0015), but no change was seen in UC mucosa.
|
23594276 |
2013 |
|
Ulcerative Colitis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Panx1 expression was reduced in Crohn's disease but not ulcerative colitis.
|
22426419 |
2012 |
|
Crohn Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
There was reduced Panx1 protein expression in CD muscularis, but no change in CD mucosa, UC muscularis, or UC mucosa.
|
23594276 |
2013 |